Technical Analysis for OBLN - Obalon Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.39 -7.39% -0.03
OBLN closed down 7.39 percent on Monday, May 20, 2019, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 23

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical OBLN trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -7.39%

Older signals for OBLN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Medicine Surgery Obesity Manufactured Goods Bariatrics Gastric Balloon Toy Balloon
Is OBLN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.7
52 Week Low 0.37
Average Volume 369,088
200-Day Moving Average 1.7816
50-Day Moving Average 0.8716
20-Day Moving Average 0.4716
10-Day Moving Average 0.4791
Average True Range 0.0734
ADX 39.87
+DI 14.1425
-DI 34.2515
Chandelier Exit (Long, 3 ATRs ) 0.4198
Chandelier Exit (Short, 3 ATRs ) 0.5902
Upper Bollinger Band 0.5604
Lower Bollinger Band 0.3828
Percent B (%b) 0.04
BandWidth 37.659033
MACD Line -0.1054
MACD Signal Line -0.1288
MACD Histogram 0.0235
Fundamentals Value
Market Cap 6.56 Million
Num Shares 16.8 Million
EPS -2.31
Price-to-Earnings (P/E) Ratio -0.17
Price-to-Sales 28.14
Price-to-Book 2.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.45
Resistance 3 (R3) 0.45 0.43 0.44
Resistance 2 (R2) 0.43 0.41 0.43 0.44
Resistance 1 (R1) 0.41 0.41 0.40 0.41 0.43
Pivot Point 0.39 0.39 0.39 0.39 0.39
Support 1 (S1) 0.37 0.37 0.36 0.37 0.35
Support 2 (S2) 0.35 0.37 0.35 0.34
Support 3 (S3) 0.33 0.35 0.34
Support 4 (S4) 0.33